Table of Contents
PPT Slide
PPT Slide
Agenda
Ligand’s Core Strategy: Build Two Diversified Profit Centers
Our Strategy is Paying Off
PPT Slide
PPT Slide
PPT Slide
PPT Slide
Our Pipeline is Among Biotech’s Best
PPT Slide
PPT Slide
We Are Approaching Operating Break-Even on a Quarterly Basis
Agenda
PPT Slide
Morphelan™ Will Contribute Significant Value to our LSPP Portfolio
Morphelan Product Profile
PPT Slide
Morphelan Versus OxyContin
SR Opioid Market is Growing Rapidly
2001 SR Opioid $ Market Share ($mm)
Oncology Pain Market Assessment
Ligand Sales Force Strategy for Morphelan
LSPP Development Priorities
ONTAK Has Significant Potential in Other Cancers, Autoimmune Diseases
ONTAK Growth in Expanded Use
Targretin Gel Has Exciting Potential in Dermatologic Disorders
Targretin Capsules Have Enormous Potential in Lung Cancer
Market Opportunity Non-Small Cell Lung Cancer (NSCLC)
Benefit of Targretin® Capsules in NSCLC
NSCLC Phase III Registration Program for First-Line Therapy
Agenda
PPT Slide
LCPP Products May be Breakthroughs in Several Fields
LCPP Pipeline is Poised to Deliver Major Royalty, Milestone Income
Market Opportunity Osteoporosis / Osteopenia
Market Opportunity HRT (Female)
Ligand Partners’ Second Generation SERMs
Benefits of Lasofoxifene
PPT Slide
TSE-424 vs. Raloxifene Activity on Bone Markers
TSE-424 / PREMARIN® Combination: New Concept in HRT
PPT Slide
PPT Slide
Continuum of Excellence in Women’s Health Products
Therapeutic Advantages of Second Generation SERMs
Market Opportunity Diabetes and Dyslipidemias
Ligand’s Partnered Drugs for Diabetes / Dyslipidemias
Ligand / TAP Pharmaceutical Products Collaborative Research Program
Ligand / TAP Pharmaceutical Products Collaborative Research Program
Agenda
Historical Financial Results
Ligand Pharmaceuticals Incorporated Income Statement and Balance Sheet
What’s Next for Ligand?
PPT Slide
Strategic Priorities 2002-2004
Upcoming Value Driving Events
Upcoming Value Driving Events
PPT Slide
|